(VIANEWS) – FibroGen (NASDAQ: FGEN) shares have experienced a dramatic 30.95% decrease over 21 sessions. From EUR1.26 on August 21st to EUR0.87 at 18:24 EST on Wednesday night is just 39%. While FibroGen itself saw its shares dip 50.41% from its 52-week high of EUR25.69; investors and analysts alike have expressed significant concern regarding this company’s future prospects.
About FibroGen
FibroGen is a biopharmaceutical company focused on meeting unmet medical needs through innovative therapeutics. Their lead products, Pamrevlumab and Roxadustat, are in Phase III clinical development for multiple indications, such as idiopathic pulmonary fibrosis, pancreatic cancer, Duchenne muscular dystrophy anemia in chronic kidney disease or myelodysplastic syndromes. FibroGen has partnerships with Astellas Pharma and AstraZeneca; established since 1993 and headquartered out of San Francisco
Yearly Analysis
Based on the provided data, FibroGen’s stock is underperforming compared to its 52-week high but outperforming its 52-week low performance. Unfortunately, EBITDA for FibroGen’s shares is negative which should raise concern among investors.
FibroGen anticipates modest sales growth of 10.1% this year and 9.5% next year; although this figure may help compensate for its negative EBITDA margin.
FibroGen investors should exercise extreme caution before considering investing in this company, due to the negative EBITDA and underperformance relative to its 52-week high, as these may be warning signals and investors should carefully evaluate both financial health and growth prospects before making any investments decisions.
Technical Analysis
Investors tracking FibroGen (EPA:FIB) may have noticed its stock has recently experienced a steep decrease. At EUR1.04 its current stock price falls significantly below its 50-day moving average of EUR1.64 and far beneath its 200-day moving average of EUR13.89.
This downward trend can also be seen in the company’s trading volume, which today was 27,65% lower than its average of 4,800,720. A drop like this may suggest investors’ lack of trust for its stock, contributing to its decline.
FibroGen stock’s intraday volatility has been relatively stable over the last week, month, and quarter with average fluctuations ranging between 5.50%, 3.29% and 5.12% respectively – suggesting relatively minor fluctuations in value over this time frame. However, its highest amplitude of average volatility was recorded as 5.50 (Week 1), 7.10% (Month) and 5.12% (Quarter). These figures suggest it could experience greater price movement soon.
According to the stochastic oscillator, which measures overbought and oversold conditions, FibroGen’s stock is currently considered overbought (>=80), suggesting a potential price correction may occur soon as investors sell off positions in anticipation of potential price decrease.
Quarter Analysis
FibroGen has experienced impressive sales and revenue growth over recent quarters. Their current quarterly sales growth stands at 134.11% while they expect this upward trend to continue, as indicated by estimates of 30.6% and 47.1% growth in subsequent quarters respectively.
FibroGen’s year-on-year quarterly revenue growth of 48.7% during the past twelve months exemplifies their ability to achieve consistent revenue growth, likely driven by strong market conditions, successful product launches and effective marketing and sales strategies.
Overall, investors should closely track FibroGen’s continued expansion trajectory and determine its effects on its future earnings potential and financial performance.
Equity Analysis
According to FibroGen’s financial data, its trailing twelve months EPS stands at -$2.91, which indicates it has experienced losses recently. Investors should take this information into consideration as it reveals whether or not FibroGen can generate profits for its shareholders; however, one or two poor quarters or years may simply indicate temporary setbacks; therefore investors must carefully study FibroGen’s financial performance over a longer timeframe before making informed decisions about FibroGen.
FibroGen’s Return on Equity (ROE) over the past twelve months stands at negative -1015.79%, suggesting it has failed to generate profits for shareholders. ROE measures profitability relative to shareholder equity; when negative, this could indicate that their equity isn’t being utilized effectively enough to generate profits; it is important, like with EPS numbers, to analyze these over time and assess if it represents a long-term trend or temporary setbacks.
FibroGen’s recent financial performance has been dismal, with an annualized trailing twelve month earnings per share (EPS) loss of -$2.91 and negative return on equity (ROE) of -1015.79%. While this information should be carefully evaluated before making a long-term investment decision.
More news about FibroGen (FGEN).
